Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
ID: HT9402-26-Q-9101Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYAURORA, CO, 80011, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/workspace/contract/opp/93700573373f4c5ba89750ce9466b1ca/view
Timeline
    Description

    The Department of Defense, through the Defense Health Agency (DHA), is soliciting quotes for a Blanket Purchase Agreement (BPA) and an Additional Discount Program (ADP) for pharmaceutical agents to be included in the DoD Uniform Formulary (UF). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on oncological agents for myelofibrosis and antihemophilic agents, with evaluations based on clinical and cost-effectiveness. Interested vendors must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025. For further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.

    Point(s) of Contact
    Tracy Banks
    tracy.e.banks2.civ@health.mil
    Stephanie Erpelding
    stephanie.j.erpelding.civ@health.mil
    Files
    Title
    Posted
    A0001 February 2026 PandT Meeting Reporting.xlsx
    The document, titled "Pharmacy Operations Support Contract (POSC) - February 2026 P&T Meeting Reporting," details limitations and data related to the Military Health System (MHS) Pharmacy Data Transaction Service (PDTS). The PDTS is an integrated system for patient eligibility, safety concerns (drug interactions, dosages), and reimbursement. However, it has limitations for research due to continuous updates and its primary design for patient safety during claims processing. Key limitations include unpicked-up prescriptions remaining active, changes in dispensing procedures affecting figures (e.g., 90-day to 30-day supply), inability to differentiate acute vs. chronic use, unknown off-label uses, and impact from mobile populations. The report covers data from October 1, 2024, to September 30, 2025, and was last updated on November 25, 2025. It provides detailed tables and charts for Antihemophilic Agents Subclass Non-Factor Agents and Oncological Agents Subclass Myelofibrosis, listing brand and generic names, strengths, dosage forms, manufacturers, and dispensed quantities across different service categories (retail, mail order, MTF) and quarters.
    A0001 HT9402-26-Q-9101 Amend.pdf
    The Defense Health Agency issued Amendment HT9402-26-Q-9101 0001 on December 3, 2025, to solicitation HT9402-26-Q-9101. The amendment's sole purpose is to incorporate the February 2026 Pharmacy and Therapeutics (P&T) utilization reporting into the existing solicitation. All other terms and conditions of the original solicitation remain unchanged.
    NDC Price List FAQ Class Review.pdf
    This document outlines instructions for filling out price appendices for government RFPs, specifically for Blanket Purchase Agreements (BPAs) and Average Dealer Price (ADP) submissions. For BPAs, vendors must complete yellow cells, which include package size and price per NDC, with the latter highlighting red if no quote is submitted for a condition set. The price per unit is auto-calculated. For ADP, vendors input non-FAMP and Federal Ceiling Prices, with a 0.0000% additional offered refund highlighting red if no quote is submitted. Total calculated refunds are auto-calculated. Both appendices provide tables for up to 10 NDCs; vendors needing more must contact the listed POCs. Formulary Notes in both sections offer insight into the P&T committee's decision-making process.
    NDC Price List-Antihemophilic Agents - Non-factor Agents.xlsx
    The Department of Defense (DOD) Uniform Formulary Class for ANTIHEMOPHILIC AGENTS, specifically NON-FACTOR AGENTS, is undergoing review by the P&T Committee from February 4-5, 2026. Quotes for this review are due by January 16, 2026. The document outlines various scenarios for formulary status (Uniform Formulary Before-Step, After-Step, and Non-Formulary After-Step) for Military Treatment Facility and Mail Order, indicating that "NO QUOTE" has been submitted for all listed NDC numbers across these scenarios. It also details the TRICARE Retail Refund scenarios for Tier 2 (Before-Step and After-Step) and Tier 3 (After-Step) agents, with similar indications of no quotes. Key notes include the potential for Prior Authorization (PA), special reimbursement methods, consideration of preferential status for non-generic agents (Tier 1), and possible exclusion from the TRICARE pharmacy benefit program. Step Therapy with a grandfathering process is outlined, requiring new patients to trial step-preferred agents. Manufacturers are reminded to submit fully executed signature pages with quote information, and the price per unit will be consistent across package sizes for a given dosage form and strength.
    NDC Price List-Oncological Agents - Myelofybrosis.xlsx
    The document outlines the Department of Defense (DOD) Uniform Formulary Class review for Oncological Agents, specifically for the Myelofibrosis subclass. It details the process for a Blanket Purchase Agreement (BPA) Appendix and an Additional Discount Program (ADP) Appendix. Key dates include a P&T Committee Meeting on February 4-5, 2026, and a quote due date of January 16, 2026. The document specifies various scenarios for drug inclusion in the Uniform Formulary (UF) and outlines conditions for both before-step and after-step therapy agents, as well as uniform and non-formulary options. It also introduces a step therapy addendum with grandfathering provisions and notes that prior authorization may apply. Manufacturers are instructed to submit fully executed signature pages with their quotes, and pricing for pharmaceutical agents will be consistent across all package sizes within a given dispensing venue. The ADP section details TRICARE Retail Refund scenarios for Tier 2 and Tier 3 drugs, including how total calculated refunds are derived based on Non-FAMP and Federal Ceiling Price.
    RFQ HT9402-26-Q-9101 CR.pdf
    The Department of Defense (DoD) Defense Health Agency (DHA) has issued a Request for Quotation (RFQ) for pharmaceutical agents to be included in the DoD Uniform Formulary (UF). This RFQ outlines the process for manufacturers to submit offers, including UF Blanket Purchase Agreements (BPA) for Military Treatment Facilities (MTF) and TRICARE Mail Order Pharmacy (TMOP), and UF Additional Discount Program (ADP) agreements for the TRICARE retail network. The DoD Pharmacy and Therapeutics (P&T) Committee will evaluate pharmaceutical agents based on clinical and cost-effectiveness to determine their placement on the UF and their cost-share tier classification (generic, formulary, or non-formulary). The RFQ details submission steps, general information, points of contact, key dates, and specific instructions for both BPA and ADP quotes, emphasizing compliance and pricing requirements. It also defines terms and acronyms relevant to the DoD's pharmacy benefits program.
    Similar Opportunities
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense (DoD) is issuing a Request for Quotation (RFQ) for pharmaceutical agents to establish Blanket Purchase Agreements (BPAs) and an Additional Discount Program (ADP) as part of its Uniform Formulary for the Military Health System. This procurement aims to secure effective and cost-efficient pharmaceutical agents, including newly approved drugs for various therapeutic classes, which will be evaluated by the Pharmacy and Therapeutics (P&T) Committee for inclusion in the formulary. The selected agents will play a crucial role in providing essential medications to military personnel and their families, ensuring access to high-quality healthcare. Interested manufacturers must submit their quotes by January 5, 2026, with a pre-quotation teleconference scheduled for December 17, 2025; for further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Julia Trang at julia.n.trang.civ@health.mil.
    TRICARE Pharmacy Program RFI
    Dept Of Defense
    The Defense Health Agency (DHA) is conducting a Request For Information (RFI) for its next-generation TRICARE Pharmacy Program (TPharm) contract, aimed at gathering industry feedback to inform the program's requirements and design. The RFI focuses on key areas such as pharmacy benefit administration, mail order pharmacy fulfillment, enhanced care programs, and operational barriers affecting vendor participation in federal pharmacy contracts. This program is crucial as it serves over 9.6 million beneficiaries and integrates various pharmacy services, including retail and mail order options. Interested parties are encouraged to submit their responses via email to dha.buckley.ad-spt-cae.mbx.tpharm6@health.mil by January 30, 2026, at 12:00 pm MST, as the DHA seeks to utilize this information for market research purposes.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.
    Trazodone - Solicitation
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for Trazodone tablets in various dosages and bottle counts. This procurement aims to secure a substantial quantity of pharmaceutical supplies essential for military and healthcare operations. Offerors are required to submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by December 12, 2025, at 3:00 PM EST, with no alternative submission methods accepted. Interested parties can reach out to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil for further inquiries regarding the solicitation.
    DLA MedSurg Prime Vendor Gen VI
    Dept Of Defense
    The Defense Logistics Agency (DLA) is seeking proposals for the Medical Surgical Prime Vendor (Med/Surg PV) Program, which aims to provide medical and surgical supplies across three Global Regions: North, South, and West. This procurement involves awarding Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for both Primary and Backup vendors, facilitating the delivery of a wide range of commercially available medical supplies to various military and federal healthcare facilities. The program is crucial for ensuring that Medical Treatment Facilities (MTFs) and operational customers have timely access to essential medical products, thereby supporting military readiness and healthcare operations. Interested vendors must submit their proposals electronically via the DLA Internet Bid Board System (DIBBS) by January 8, 2026, at 3:00 PM Local Philadelphia Time, and can direct inquiries to Beatrice Lopez-Pollard at beatrice.lopez-pollard@dla.mil or Joshua Tankel at Joshua.Tankel@dla.mil.
    Metaxalone Tablets
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for Metaxalone Tablets, specifically 800 MG tablets available in 100-count and 500-count bottles. This procurement aims to secure a reliable supply of this pharmaceutical product, which is essential for various medical applications within military healthcare. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between November 7 and December 7, 2025, by 3:00 PM EST, and are required to adhere to specific contract terms, including a subcontracting plan for large businesses and compliance with various federal regulations. For further inquiries, potential offerors can contact Jeremy Brown at jeremy.brown@dla.mil or Jason Wray at Jason.wray@dla.mil.
    6505--766-26-1-400-0207 -Charleston CMOP 2 Pharmaceuticals -(VA-26-00025368)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking to procure two specific pharmaceuticals, JASMIEL (J0040) 28-DAY TABLET and DROSPIRENONE 4MG (D1217), for the Consolidated Mail Outpatient Pharmacy (CMOP) in Ladson (Charleston). This procurement is critical as the products have been prescribed by VA physicians, and no substitutions are permitted due to the absence of alternative suppliers in the market. Vendors are required to submit a signed SF1449, a completed pricing schedule, a valid State Wholesale Distributor License, and a Buy American Act Certificate by January 5, 2026, at 3:00 PM CT, with deliveries staggered over a six-month period starting ten days after order receipt. Interested parties should direct their quotes to Kelley Cunningham at kelley.cunningham@va.gov.
    Rabeprazole Sodium Delayed Release Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Pharmacy Data Warehouse
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is seeking to extend the contract for the Pharmacy Data Warehouse (PDW) managed by General Dynamics Information Technology, Inc. (GDIT) for an additional 16 months, until July 24, 2024. This bridge action is necessary to maintain the continuity of services related to the management of TRICARE pharmacy transaction data, which is critical for ensuring patient safety and supporting various analyses related to drug utilization and fraud prevention. The extension is vital to avoid disruptions that could impact the Federal Pricing Refund Program and the Military Health System's readiness tools, as well as to fulfill congressional reporting requirements. Interested parties can contact Viktoria Reed at viktoria.s.reed.civ@health.mil or call 303-676-3648 for further information.